{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:20:46Z","timestamp":1772119246125,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Studies evaluating inter-institutional discrepancies in muscle-invasive bladder cancer diagnosis, particularly when radical cystectomy is recommended, are scarce. In this study, we aimed to examine the inter-institutional concordance rate of pathological stages in patients diagnosed with muscle-invasive bladder cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed tissue samples from patients pathologically diagnosed with muscle-invasive bladder cancer at other hospitals who subsequently sought a second opinion at our hospital between January 1, 2013 and December 31, 2023. Data were acquired retrospectively by retrieving clinical data from medical records. We investigated the inter-institutional concordance rate of pathological stages assigned to each patient and examined the tumor characteristics and prognoses of patients with pathological stage discrepancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 170 patients evaluated, 22 (12.9%) were downstaged upon pathological examination at our hospital. The tumor characteristics of stage discrepancy cases were small tumor size, solitary lesions, and vesical imaging reporting data system score\u2009&lt;\u20093. Eleven patients were treated for non-muscle-invasive bladder cancer based on the re-evaluation findings. Eight patients had no evidence of disease, two patients had Ta bladder recurrence, and one patient had lung metastasis despite no bladder recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the importance of pathological re-evaluation of patients diagnosed with muscle-invasive bladder cancer. The significant discrepancy rate and its impact on the treatment decisions are noteworthy. Standardization of diagnostic practices is essential to mitigate variability among pathologists and facilities and to ensure optimal care for patients with muscle-invasive bladder cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05861-5","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:36:38Z","timestamp":1759998998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Second opinions and pathological review impact the clinical management of patients with muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Takashi","family":"Kawahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuya","family":"Kandori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"5861_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"5861_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Roupr\u00eat M, Shariat SF, Seisen T, Soukup V, Sylvester RJ (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81:75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"5861_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, Hern\u00e1ndez V, Linares Espin\u00f3s E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskim\u00e4e E, Ribal MJ, van der Heijden AG (2021) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79:82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","journal-title":"Eur Urol"},{"key":"5861_CR4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/iju.14281","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H (2020) Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision. Int J Urol 27:702\u2013709. https:\/\/doi.org\/10.1111\/iju.14281","journal-title":"Int J Urol"},{"key":"5861_CR5","unstructured":"Amin MB, Edge SB, Greene FL, et al. American Joint Committee on Cancer (AJCC) (2017) Cancer staging manual, 8th edn. Springer, New York"},{"key":"5861_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF (2018) Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system). Eur Urol 74:294\u2013306. https:\/\/doi.org\/10.1016\/j.eururo.2018.04.029","journal-title":"Eur Urol"},{"issue":"2","key":"5861_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2012.10.008","volume":"63","author":"DE Hansel","year":"2013","unstructured":"Hansel DE, Amin MB, Comperat E, Cote RJ, Kn\u00fcchel R, Montironi R, Reuter VE, Soloway MS, Umar SA, Van der Kwast TH (2013) A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 63(2):321\u2013332. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.008","journal-title":"Eur Urol"},{"key":"5861_CR8","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/1097-0142(20010401)91:7<1284::AID-CNCR1130>3.0.CO;2-E","volume":"91","author":"TR Coblentz","year":"2001","unstructured":"Coblentz TR, Mills SE, Theodorescu D (2001) Impact of second opinion pathology in the definitive management of patients with bladder carcinoma. Cancer 91:1284\u20131290. https:\/\/doi.org\/10.1002\/1097-0142(20010401)91:7%3c1284::AID-CNCR1130%3e3.0.CO;2-E","journal-title":"Cancer"},{"key":"5861_CR9","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1097\/00005392-200011000-00017","volume":"164","author":"A Van Der Meijden","year":"2000","unstructured":"Van Der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F (2000) The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 164:1533\u20131537. https:\/\/doi.org\/10.1097\/00005392-200011000-00017","journal-title":"J Urol"},{"key":"5861_CR10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/01.ju.0000055471.78783.ae","volume":"169","author":"MG Bol","year":"2003","unstructured":"Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O, \u00d8greid P (2003) Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 169:1291\u20131294. https:\/\/doi.org\/10.1097\/01.ju.0000055471.78783.ae","journal-title":"J Urol"},{"key":"5861_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1464-410X.2009.09100.x","volume":"106","author":"BWG van Rhijn","year":"2010","unstructured":"van Rhijn BWG, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, Bangma CH, Jewett MA, Zlotta AR (2010) Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 106:206\u2013211. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.09100.x","journal-title":"BJU Int"},{"key":"5861_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.juro.2009.11.049","volume":"183","author":"MC Lee","year":"2010","unstructured":"Lee MC, Levin HS, Jones JS (2010) The role of pathology review of transurethral bladder tumor resection specimens in the modern era. J Urol 183:921\u2013927. https:\/\/doi.org\/10.1016\/j.juro.2009.11.049","journal-title":"J Urol"},{"key":"5861_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.urology.2016.01.048","volume":"93","author":"AM Luchey","year":"2016","unstructured":"Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA (2016) Change in management based on pathologic second opinion among bladder cancer patients presenting to a comprehensive cancer center: implications for clinical practice. Urology 93:130\u2013134. https:\/\/doi.org\/10.1016\/j.urology.2016.01.048","journal-title":"Urology"},{"key":"5861_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5489\/cuaj.4126","volume":"11","author":"SL Traboulsi","year":"2017","unstructured":"Traboulsi SL, Brimo F, Yang Y, Maedler C, Pr\u00e9vost N, Tanguay S, Aprikian AG, Kassouf W (2017) Pathology review impacts clinical management of patients with T1\u2013T2 bladder cancer. Can Urol Assoc J 11:188\u2013193. https:\/\/doi.org\/10.5489\/cuaj.4126","journal-title":"Can Urol Assoc J"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05861-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05861-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05861-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:03:32Z","timestamp":1767999812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05861-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5861"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05861-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4830148\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the University of Tsukuba Hospital, Japan (approval number: H29-030). Informed consent was obtained using an opt-out method via the hospital website. Patients who declined participation were excluded from the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participant"}}],"article-number":"602"}}